Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
News
Research News
Conference News
Plain English
Forums
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
Interviews
Resources
What We Know
SchizophreniaGene
Animal Models
Drugs in Trials
Research Tools
Grants
Jobs
Conferences
Journals
Community Calendar
General Information
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
History
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Annotation

Kunii Y, Hyde TM, Ye T, Li C, Kolachana B, Dickinson D, Weinberger DR, Kleinman JE, Lipska BK. Revisiting DARPP-32 in postmortem human brain: changes in schizophrenia and bipolar disorder and genetic associations with t-DARPP-32 expression. Mol Psychiatry . 2013 Jan 8 ; PubMed Abstract

Comments on Paper and Primary News
Primary News: DARPP-32 Isoform Elevated in Psychiatric Disorders

Comment by:  Jamal NasirNirmal Vadgama
Submitted 8 March 2013 Posted 8 March 2013

Kunii et al. used two different TaqMan Assays (Applied Biosystems) to compare expression levels of full-length (FL) and truncated DARPP-32 (t-DARPP-32) in various regions of the brain, and detected increased expression of t-DARPP-32 in DLPFC in both schizophrenia and bipolar disorder samples compared to controls. Overexpression of genes can cause developmental abnormalities in the brain. For example, increased LIS1 expression can lead to significant brain abnormalities in humans and mice (Bi et al., 2009).

We previously showed increased expression of DARPP-32 in human DLPFC tissue from both schizophrenia (n = 33) and bipolar disorder (n = 32) samples using the same TaqMan assay (Hs00259967_ml) as above (this detects both FL-DARPP-32 and t-DARPP-32), after excluding brain weight, age of onset, postmortem interval, time in hospital, duration of illness and antipsychotics, gender, race, smoking, alcohol, drugs, suicide status, family history, insight and psychotic features as potential confounding factors (  Read more


View all comments by Jamal Nasir
View all comments by Nirmal Vadgama
Submit a Comment on this Paper
Make a comment on this paper. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Affiliation  
Country or Territory  
*Login Email Address  
*Confirm Email Address  
*Password  
*Confirm Password  
Remember my Login and Password?  
Get SRF newsletter with recent commentary?  
 
Enter the code as it is shown below:
This code helps prevent automated registrations.

I recommend this paper

Please note: A member needs to be both registered and logged in to submit a comment.

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


 
 
SRF News
SRF Comments
Text Size
Reset Text Size
Email this pageEmail this page

Share/Bookmark
 
Copyright © 2005- 2014 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright